Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gardasil Anal Cancer Indication: CBER Has No Concerns, But What Will ACIP Think?

Executive Summary

A Center for Biologics Evaluation and Research clinical reviewer sees no problem with using an anal dysplasia endpoint, or extrapolating male data to females, to support approval of Merck’s human papillomavirus vaccine Gardasil for prevention of anal cancer.

You may also be interested in...



Gardasil Anal Cancer Indication Passes FDA Muster; Next Stop Is ACIP

Expanded indication does not actually expand the target population for the HPV vaccine, but the data should bolster Merck's argument for a routine vaccination recommendation in males when it goes before CDC's Advisory Committee on Immunization Practices.

FDA Committee Endorses Gardasil Anal Cancer Indication For Males And Females

Most members of the Vaccines and Related Biological Products Advisory Committee agreed that similarities in the disease across genders supported extrapolating male-only study data on the HPV vaccine to females.

Gardasil Anal Cancer Indication To Face FDA Advisory Committee Scrutiny

Supplemental application filed earlier this year is part of Merck's strategy to broaden use of the HPV vaccine, although its bid to expand the label to women ages 27-45 has thus far been blocked by the agency.

Related Content

Topics

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel